Abstract:Abstract Purpose: Microsatellite instability (MSI) was the FDA-approved companion diagnostic biomarker for using pembrolizumab in solid tumors and the biomarker for Lynch Syndrome. Next-generation sequencing (NGS) based method was recommended by NCCN and ESMO for detecting MSI status due to rich mutation information it could provide. However, current NGS based methods could be discordant on some cases, triggering confusion in clinical practice. To address this concern, we developed a novel and highly accurate MSI detection method, 3D-MSI, with a set of well-selected loci and compared its performance with other 3 public methods (MANTIS, MSISensor2, mSINGS) Materials and Methods: 100 MSI loci were selected from 2539 candidates and then sequenced on 145 FFPE samples as the training dataset. A binomial distribution model was built on each loci to predict PCR-validated MSI statuses of all samples in the training dataset and then all models were ordered by their prediction accuracy. 3D-MSI method determined MSI status by the percentage of top 30 loci models which predict the sample as MSI-H (>40%: MSI-H; otherwise MSS). Performances of 3D-MSI and other 3 methods were compared on 485 MSI-validated sample. Their discordance were further investigated on a large cohort of 10399 Chinese cancer patients. Detection limits of these 4 methods were determined by 4 serial-diluted tumor samples. We also observed concordance between 3D-MSI detected statuses and immunotherapy response on 27 advanced colorectal cancer (CRC) patients. Results: In the dataset of 485 samples, 3D-MSI had the highest accuracy (All: 96.7%, Colorectal cancer CRC: 98.9%, Gastric cancer GC: 97.0%, other cancer: 86.4%), sensitivity (All: 93.2%, CRC: 97.0%, GC: 94.4%, Other: 80.8%) and specificity (All: 98.2%, CRC: 99.5%, GC: 98.8%, Other: 90.0%) among all 4 methods. It could detect correct MSI status under low tumor content down to 5%, but other methods required much higher tumor content to work (MSISensor2: ≥15%, mSINGS: ≥20%, MANTIS: ≥40%). Study on 10399 Chinese cancer patients confirmed superiority of 3D-MSI: compared with other 3 methods, it yielded the fewest discordant and unreliable MSI statuses questioned by PCR (3D-MSI: 1, MSISensor2: 36, mSINGS: 36, MANTIS: 50). Loci selection was the key point for 3D-MSI to outrival other 3 methods, revealed by comparing their scoring distribution. 3D-MSI detection predicted significantly prolonged PFS (log-rank P<0.0001) and OS (log-rank P<0.0001) of the MSI-H group in 27 CRC patients who received immunotherapy, proving its validity in clinical practice. Conclusions: Our study offered an improved and clinically validated method for NGS-based MSI detection and stressed importance of loci selection in MSI detection, which would have crucial implications for future research and clinical management. Citation Format: Jian Li, Zhenghang Wang, Bo Yang, Bin Li, Yunjie Song, Bei Zhang, Xiaochen Zhao, Yifan Zhou, Zhenghua Xie, Xiaofang Li, Hao Chen, Hua Dong, Yuezong Bai, Lei Xiong, Fugen Li, Jing Gao, Lin Shen. A novel loci-selected method for microsatellite instability detection validated on a large Chinese cohort [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5477.

Bmsi Better Predicts the Responses to Immune Checkpoint Inhibitors (ICI) Than MMR/MSI from Historical Tissue Specimens in Metastatic Gastrointestinal Cancer Patients.

Plasma-based Microsatellite Instability Detection Strategy to Guide Immune Checkpoint Blockade Treatment

Effect of Exonic Microsatellite Instability of B2M on the Predictability of MSI/dMMR for Immunotherapy.

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Evaluation of blood MSI burden dynamics to trace immune checkpoint inhibitor therapy efficacy through the course of treatment

Abstract 5477: A Novel Loci-Selected Method for Microsatellite Instability Detection Validated on a Large Chinese Cohort

A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer

Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study

Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors

Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with gastrointestinal (GI) cancers.

Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer

Dynamic Peripheral Blood Immune Cell Markers for Predicting the Response of Patients with Metastatic Cancer to Immune Checkpoint Inhibitors

Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Prognosis and immunotherapy efficacy in dMMR&MSS colorectal cancer patients and an MSI status predicting model

Large-Scale Cancer Genomic Analysis Reveals Significant Disparities Between Microsatellite Instability and Tumor Mutational Burden

Combination of AKT1 and CDH1 Mutations Predicts Primary Resistance to Immunotherapy in Dmmr/msi-H Gastrointestinal Cancer

Multi-omics Characterization and Validation of MSI-related Molecular Features Across Multiple Malignancies

Identification of the molecular characteristics associated with microsatellite status of colorectal cancer patients for the clinical application of immunotherapy

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers

Efficacy and Safety of Immune Checkpoint Inhibitors in Proficient Mismatch Repair (pmmr)/ Non-Microsatellite Instability-High (Non-Msi-h) Metastatic Colorectal Cancer: a Study Based on 39 Cohorts Incorporating 1723 Patients.

Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes